Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - leukemiavirusta rekombinantti canarypox-virus (vcp97) - immunologisia valmisteita varten felidae, - kissat - aktiivinen immunisaatio 8 viikon ikäisten tai vanhempien kissojen leukemiaa vastaan ​​jatkuvan viraemian ja siihen liittyvän taudin kliinisten oireiden ehkäisemiseksi. immuniteetin puhkeaminen on osoitettu 2 viikon kuluttua perusrokotuskurssista. immuniteetin kesto on yksi vuosi viimeisestä rokotuksesta.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65-virus - immunologian osalta - kissat - aktiivinen immunisaatio kissoille, jotka ovat 12 viikon ikäisiä ja vanhempia raivotaudin aiheuttaman kuolleisuuden ehkäisemiseksi. immuniteetin aloitus: 4 viikkoa primaarisen rokotuskurssin jälkeen. immuniteetin kesto perusrokotuksen jälkeen: 1 vuosi. immuunijäljittymisen jälkeinen kesto: 3 vuotta.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - telmisartan - agentit reniini-angiotensiini-järjestelmä, angiotensiini ii-antagonistit, pelkkä - kissat - krooniseen munuaissairauteen (ckd) liittyvän proteinurian väheneminen.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinantti kalkkunan herpesvirus, kanta vhvt013-69, live - immunologisia valmisteita varten aves, kanoja, immunologisia valmisteita - embryonated eggs; chicken - kanojen aktiivinen immunisointi:ehkäisemään kuolleisuutta ja vähentämään kliinisiä oireita ja leesioita gumboron tauti. vähentää kuolleisuutta, kliinisiä oireita ja vaurioita marekin tautia.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamitromysiinille - systeemiseen käyttöön tarkoitetut antibakteerit - cattle; pigs; sheep - cattletreatment ja metaphylaxis naudan hengitystieinfektion (brd: n) on mannheimia haemolytica -, pasteurella multocida-ja histophilus somni. taudin läsnäolo karjassa olisi vahvistettava ennen metafylaktista käyttöä. pigstreatment sian hengitysteiden sairaus (srd) liittyy actinobacillus pleuropneumoniae, pasteurella multocida -, haemophilus parasuis-ja bordetella bronchiseptica. sheeptreatment tarttuvien pododermatitis (foot rot) liittyy elinvoimaiset dichelobacter nodosus-ja fusobacterium necrophorum, joka vaatii systeemistä hoitoa.

Euroopan unioni - suomi - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - diabeetilla käytettävät lääkkeet - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.